Matt Larew analyst WILLIAM BLAIR

Currently out of the existing stock ratings of Matt Larew, 1 are a HOLD (100%).

Matt Larew

Work Performance Price Targets & Ratings Chart

Analyst Matt Larew, currently employed at WILLIAM BLAIR,

Matt Larew has documented 2 price targets and ratings displayed on 9 stocks.

Most recent stock forecast was given on AMED, at 30-Dec-2024.

Wall Street Analyst Matt Larew

Analyst best performing recommendations are on DNA (GINKGO BIOWORKS HOLDINGS).
DNA Ginkgo Bioworks Holdings INNV SGFY ZY MRVI DVA MXCT USPH AMED

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sell Since 26-Jun-2024

$5

$-2.46 (-32.98%)

$5

2 months 17 days ago
(04-Sep-2026)

4/9 (44.44%)

$-1.95 (-28.06%)

50

Buy Since 20-Sep-2024

$9

$1.54 (20.64%)

$12

3 months 14 days ago
(07-Aug-2026)

3/3 (100%)

$1.03 (12.92%)

129

Buy Since 01-Mar-2022

$3

$120

2 years 2 months 4 days ago
(17-Sep-2024)

0/5 (0%)

$-3.81 (-55.95%)

Sell Since 20-Aug-2024

$7

2 years 3 months 1 days ago
(20-Aug-2024)

1/1 (100%)

$-0.71 (-9.21%)

10

Hold Since 04-Oct-2022

$40

$40

2 years 3 months 1 days ago
(20-Aug-2024)

0/4 (0%)

$32.29 (418.81%)

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Matt Larew?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?